Purpose To describe the incidences of hypogonadism, hypertension, and dyslipidaemia in
patients with stage 1 seminoma (S1S) testicular cancer (TC) treated with a risk-adapted …

Purpose Clinical stage (CS) 1 testicular seminoma is cured in almost 100% of cases
following either retroperitoneal radiotherapy, carboplatin monotherapy, or surveillance …

Objectives. Adjuvant radiotherapy produces excellent disease-free rates in clinical Stage I
seminoma. However, concern is growing about side effects and late hazards of this …

Purpose To assess the efficacy of a risk-adapted treatment policy for patients with stage I
seminoma by using universally accepted risk criteria. Patients and Methods Between 1999 …

Abstract Purpose Clinical stage 1 (CS1) testicular seminoma involves an almost 100%
disease-specific survival in controlled clinical trials. We aimed to find out whether these …

Purpose The cure rate of stage I seminoma patients is close to 100% and so the recent focus
of clinical research has shifted onto the prevention of treatment-related complications. We …

4518 Background: Patients with stage I seminoma can be managed with surveillance,
prophylactic irradiation or adjuvant chemotherapy. In a previous GG trial (Ann Oncol 2003; …

Purpose Following the establishment of adjuvant carboplatin in stage I testicular seminoma
as a standard, we adopted this treatment for all stage I seminoma patients. We report our 8 …

Purpose To confirm the efficacy of a risk-adapted treatment approach for patients with
clinical stage I seminoma. The aim was to reduce both the risk of relapse and the proportion …

Systematic active surveillance (AS) and risk-adapted adjuvant chemotherapy (RAAC) with
carboplatin have become the most widely used, standard options for patients with stage I …